Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Manufactures and sells pharmaceuticals

Meiji Co., Ltd. produces and sells milk, dairy, confectioneries, and food. Its products include cheese, ice cream, chocolate, infant formula, whey protein, beauty supplements, and yogurt. The company was founded on December 21, 1917 and is headquartered in Tokyo, Japan.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

A. Carlsson Research AB, part of NTG Nordic Transport Group A/S, is a Swedish company located in Gothenburg that develops and discovery and clinical development of new pharmacological treatment principles for psychiatric and neurological disorders. Arvid M. Carlsson is currently the CEO of the firm. NTG Nordic Transport Group An acquired A. Carlsson Research AB on October 23, 2006 for $121.91 million.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Synthonics is a privately-held specialty pharmaceutical company that focuses on the discovery and development of patentable drugs that incorporate proprietary metal coordination chemistry. It binds metals to known pharmaceutical agents to create new products that are better absorbed and thus have greater therapeutic benefits than their predecessors.

Ichimaru Pharcos Co. Ltd. is a Japanese private company. The firm specializes in research and development, manufacturing and selling of raw materials for cosmetics, health foods and quasi drugs.

MSD R&D (China) Co., Ltd., established on 2012-03-21, Business scope includes medicine and pharmaceutical research and development;Medicine and Medical Consulting Services;Import and export,Technology Import and Export,Agent import and export(Involves quota license management,Commodities managed by special regulations shall be handled in accordance with relevant state regulations).(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Jinan Microscopic Intelligent Technology Co., Ltd., established on 2017-06-29, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technology Import and Export;Import and export;software development;Computer System Services;Retailing of computer software, hardware and auxiliary equipment;Machinery sales;Daily necessities sales;Business Management Consulting;electronics sales;Hardware retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Production of Class III Medical Devices;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Manufactures, marketes and imports, exports pharmaceutical drugs